Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?

Executive Summary

Lawmakers inquire about expanding pre-submission meetings to include non-complex priority ANDAs, suggesting it could be another way to help deal with drug pricing issues.


Related Content

FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Biosimilars: Next User Fee Cycle Will Be Judged On US FDA's Approvals, Rep. Burgess Says
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
US FDA May Find Relief From Trump's Hiring Freeze
PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications
Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts